Merck & Co., Inc. vs NetApp Inc. — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while NetApp Inc. trades at $231.07 (market cap $45.38B). The key difference: Merck & Co., Inc. is far larger — about 7.7× NetApp Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NetApp Inc. for 57 Days on average.
| MRK | NTAP | |
|---|---|---|
Market Cap | $351.28B | $45.38B |
Volume | 7,969,665 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $156.43 | $235.84 |
52-Week Low | $82.49 | $94.11 |
Typical Hold Time | 98 Days | 57 Days |
Enterprise Value | $398.04B | $44.34B |
Dividend Yield | 2.39% | 0.9% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
NetApp (NTAP) trades at $235.84, up 3.23% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support near $233 and resistance at $239. Fundamentals are robust with a 70.63% gross margin and 19.19% net income margin, though valuation multiples like the 33.3 P/E are elevated. Recent news highlights strategic AI partnerships and product launches, including Novus storage for AI infrastructure, driving positive sentiment.
Outlook is positive given earnings momentum and AI-driven growth, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed with a $219.30 price target below current levels, suggesting caution despite bullish technicals. Institutional ownership trends and cash flow improvements support stability, but investors should weigh growth prospects against premium pricing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →